Game-changing specialty diagnostic technology

neurology | gastroenterology | rheumatology

The Science

Diagnose Faster

Across many autoimmune diseases, reaching a diagnosis can be a complicated journey spanning months to years. Our research shows that IQIsolate may significantly shorten that timeline. 

Treat Sooner

For many autoimmune diseases, appropriate treatment at the earliest detection of disease can lead to optimal health outcomes. Our research demonstrates that IQIsolate identifies disease at the earliest onset of symptoms.


Improve Lives

Detecting disease early, implementing appropriate treatment plans at the right time and effectively managing chronic autoimmune conditions offers patients the opportunity to get back to living life.

IQuity’s Breakthrough Autoimmune Technology

IQIsolate®, is a suite of algorithms utilizing machine learning methods that analyze expression of RNA markers detected in a simple blood sample. IQuity has applied this approach to neurology, gastroenterology and rheumatology, three specialties that serve a majority of autoimmune patients.

IQuity’s technology, IQIsolate analyzes RNA expression data from a blood sample to identify presence or absence of disease at the cellular level and is representative of presence of disease in real time. IQIsolate can also distinguish among diseases in a given specialty – the gastroenterology panel can distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Within IBD, this technology can accurately distinguish Crohn’s from ulcerative colitis. With accuracy exceeding 90%, the IQIsolate process takes one week.

IQuity is firmly committed to data transparency and scientific peer review, and will perform its tests in its independent CLIA certified lab.

“Multiple Sclerosis (MS) remains a clinical diagnosis, and the certainty of the diagnosis is enhanced by imaging and electrodiagnostic studies. Any test which will increase the certainty of an MS diagnosis is of value to the treating physician. The results are likely to influence both making the diagnosis of MS and in implementing therapies that benefit the patients.”

Subramaniam Sriram, MD,
Director, MS Center,
Vanderbilt University Medical Center